Sort   by:  
 Page size 
UnknownInferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Not available
S-EPMC7914531 | biostudies-literature
UnknownTwo dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
Not available
S-EPMC5557006 | biostudies-literature
UnknownGene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
Not available
S-EPMC7594404 | biostudies-literature
ProteomicsThe M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity
Platinum-based chemotherapeutics are used in many combination regimens in cancer. Despite extensive use across diverse cancer types, there is room for improved efficacy and patient selection for treatment. Here, we use bladder cancer to address both issues. A multi-omic assessment of five human blad...
ORGANISM(S): Homo sapiens (Human) 
2024-02-20 | PXD024742 | Pride
Dna repair Lrrc8a Lrrc8d Tosedostat Volume regulated anion channel Synthetic lethality Transcriptomics Bladder cancer Genomics Chemotherapy Vrac Crispr screen Npepps Proteomics Cisplatin 
UnknownThe combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.
Not available
S-EPMC4627310 | biostudies-literature
UnknownThe expression signature, prognostic significance and immune cell infiltration of the OAS gene family in gastric cancer.
Not available
S-EPMC12612043 | biostudies-literature
TranscriptomicsThe M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity
Platinum-based chemotherapeutics are used in many combination regimens in cancer. Despite extensive use across diverse cancer types, there is room for improved efficacy and patient selection for treatment. Here, we use bladder cancer to address both issues. A multi-omic assessment of five human blad...
ORGANISM(S): Homo sapiens 
2023-12-31 | GSE171537 | GEO
OtherThe M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity. CRISPR Synthetic Lethal Screen.
Platinum-based chemotherapeutics are used in many combination regimens in cancer. Despite extensive use across diverse cancer types, there is room for improved efficacy and patient selection for treatment. Here, we use bladder cancer to address both issues. A multi-omic assessment of five human blad...
ORGANISM(S): Homo sapiens 
2023-12-31 | GSE179799 | GEO
GenomicsThe M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity. CRISPR Synthetic Lethal Screen.
The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity. CRISPR Synthetic Lethal Screen.
PRJNA745099 | ENA
GenomicsThe M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity
The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity
PRJNA719913 | ENA
Sort   by:  
 Page size